4,661 reports of this reaction
4.1% of all CABOZANTINIB reports
#4 most reported adverse reaction
NAUSEA is the #4 most commonly reported adverse reaction for CABOZANTINIB, manufactured by Exelixis, Inc.. There are 4,661 FDA adverse event reports linking CABOZANTINIB to NAUSEA. This represents approximately 4.1% of all 112,838 adverse event reports for this drug.
Patients taking CABOZANTINIB who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among CABOZANTINIB users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for CABOZANTINIB:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 4,661 FDA reports for CABOZANTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 4.1% of all adverse event reports for CABOZANTINIB, making it a notable side effect.
If you experience nausea while taking CABOZANTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.